Makeda Semret
- Jan 5, 2021
- 1 min read

Happy New year - and UPDATED COVID-19 treatment guidelines!

With the New Year, new guidelines! Our COVID-19 therapeutic working group has revised our COVID-19 management guidelines. Of note, empiric antibiotics are strongly DISCOURAGED for mild and moderate disease. Investigational or off-label therapies should NOT be given outside of clinical trials (several ongoing clinical trials at the MUHC); Criteria are proposed for potential identification of hyperimmune response, with recommendations to consult ID for severe cases.

Recent Posts

See All

COVID guidelines update and more!

The ASP Committee is happy to upload the following guidelines to the MUHC ASP website: -COVID guidelines V11 and Outpatient COVID management decision tree. -Febrile Neutropenia (update) -Antifungal p

New guidelines and update!

Do you wonder how to treat an aspiration pneumonia? What antibiotic to give in case of an open fracture? Should you give Vancomycin for the treatment of healthcare acquired meningitis? The ASP committ

Oral antiviral therapy for COVID-19? update to our management guidelines - Jan 26, 2022

Oral antiviral therapy (nirmatrelvir/ritonavir or Paxlovid) is now available in Quebec for selected patients who are at high risk of progression to severe disease AND identified early (<5days) after o